Kevin Kalinsky, MD, MS, FASCO

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (286 ratings)

Role

Medical Oncology
Specialty

Breast Cancer
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2009

Background

Kevin Kalinsky, MD, MS, FASCO, is professor and director in the Division of Medical Oncology of the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Kalinsky also serves as the director of the Glenn Family Breast Center at Winship where he is tasked with fulfilling the vision to improve breast cancer outcomes by aligning research and education with cancer treatment and prevention. A breast cancer physician and investigator, Dr. Kalinsky's research focus is in developing new therapeutic approaches to patients with breast cancer.

Dr. Kalinsky's research is in the area of new drug development and therapies for patients with early stage and metastatic breast cancer. His work involves the development clinical trials to assess novel therapeutic agents in breast cancer based on tumor genomics. He is funded by a number of sources, including the National Institutes of Health and the Breast Cancer Research Foundation.

Play Video

Titles & Roles

Professor and Director, Division of Medical Oncology, Department of Hematology and Medical Oncology

Emory University School of Medicine
Louisa and Rand Glenn Family Chair in Breast Cancer Research

Winship Cancer Institute of Emory University
Director, Glenn Family Breast Center

Winship Cancer Institute of Emory University

Education & Training

Education

Fellowship, 2009
Memorial Sloan Kettering Cancer Center
Fellowship, Hematology/Oncology, 2008
Tufts Medical Center
Residency, Internal Medicine, 2005
Tufts Medical Center
Internship, Internal Medicine, 2003
Tufts Medical Center
Medical Education, MD, 2002
Medical University of South Carolina

Research

View Current Clinical Trials


Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 Phase III Conditions Breast Cancer Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Emory Johns Creek Hospital, Grady Health System, Winship Cancer Institute
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors Phase I Conditions Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor Location Winship Cancer Institute
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study Phase III Conditions Metastatic Breast Cancer Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Emory Johns Creek Hospital, Winship Cancer Institute
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) Phase III Conditions Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Grady Health System, Winship Cancer Institute
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer Phase I/II Conditions Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer Location Winship Cancer Institute
A Study of XMT-1660 in Participants With Solid Tumors Phase I Conditions Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma Location Winship Cancer Institute
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Phase I Conditions Breast Cancer Location Winship Cancer Institute
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) Phase II Conditions HER2 Positive Metastatic Breast Cancer Location Winship Cancer Institute
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Phase II Conditions Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute

Grants

View Grants

Grant Number	Title
1R01CA249667-01A1	Tyrosine phosphorylation of p27Kip1 as a biomarker to identify Cdk4/6 inhibitor response
5R01CA249667-02	Tyrosine phosphorylation of p27Kip1 as a biomarker to identify Cdk4/6 inhibitor response
5R01CA249667-03	Tyrosine phosphorylation of p27Kip1 as a biomarker to identify Cdk4/6 inhibitor response

Publications

Title/Journal	Authors	Publication Date
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer. JCO oncology practice	A Bardia, HS Rugo, MS Sedrak, S Loibl, SM Tolaney, K Punie, SA Hurvitz, KM Kalinsky, J Cortés, JA O'Shaughnessy, V Dieras, MJ Piccart-Gebhart, A Dasgupta, A Kaushik, C Lai, L Shi, A Brufsky	06/25/2025
Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States. ESMO open	R Nanda, C Yam, L Spring, MA Bhave, I Ntalla, T Valdez, B Stwalley, C Liang, WH Wu, N Sjekloca, N Sadetsky, C Lai, K Kalinsky	06/05/2025
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study. ESMO open	L García-Estévez, A Bardia, HS Rugo, LA Carey, VC Diéras, S Loibl, M Piccart, L Gianni, K Kalinsky, J O'Shaughnessy, SA Hurvitz, E Harting, T Valdez, S Phan, C Lai, J Cortés	06/02/2025
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. The New England journal of medicine	FC Bidard, EL Mayer, YH Park, W Janni, C Ma, M Cristofanilli, G Bianchini, K Kalinsky, H Iwata, S Chia, PA Fasching, A Brufsky, Z Nowecki, J Pascual, L Moreau, SC Chen, N Karadurmus, EN Gal-Yam, KH Jung, S Pernas, S McClain, W He, T Klinowska, C Huang-Bartlett, NC Turner	06/01/2025
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer. The New England journal of medicine	KL Jhaveri, SA Im, C Saura, S Loibl, K Kalinsky, P Schmid, S Loi, E Thanopoulou, N Shankar, Y Jin, TJ Stout, TD Clark, C Song, D Juric, NC Turner	05/31/2025
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. Journal of the National Cancer Institute	Y Abdou, WE Barlow, JR Gralow, F Meric-Bernstam, KS Albain, DF Hayes, NU Lin, EA Perez, LJ Goldstein, SKL Chia, S Dhesy-Thind, P Rastogi, E Alba, S Delaloge, AF Schott, S Shak, P Sharma, DL Lew, J Miao, JM Unger, D Tripathy, GN Hortobagyi, L Pusztai, K Kalinsky	05/01/2025
MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer. Nature communications	JJ Chi, P Xie, MH Cheng, Y Zhu, X Cui, J Watson, L Zeng, A Uddin, H Nguyen, L Li, K Moremen, A Reedy, M Wyatt, A Marcus, M Dai, CM Paulos, M Cristofanilli, WJ Gradishar, S Zhao, K Kalinsky, MC Hung, I Bahar, B Zhang, Y Wan	04/15/2025
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium. Clinical breast cancer	K Jhaveri, CK Anders, A Bardia, M Bhave, AJ Chien, I Krop, TA Traina, Y Abdou, R Basho, AK Conlin, FJ Esteva, KR Fox, V Gadi, PA Kaufman, A Litvak, CX Ma, EP Mamounas, H McArthur, K McCann, Z Mitri, R Shatsky, M Telli, MA Torres, K Kalinsky	04/08/2025
Current controversies in the use of Oncotype DX in early breast cancer. Cancer treatment reviews	PPM Berton Giachetti, A Carnevale Schianca, D Trapani, A Marra, A Toss, C Marchiò, MV Dieci, OD Gentilini, C Criscitiello, K Kalinsky, JA Sparano, G Curigliano	04/01/2025
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	K Kalinsky, G Bianchini, E Hamilton, SL Graff, KH Park, R Jeselsohn, U Demirci, M Martin, RM Layman, SA Hurvitz, S Sammons, PA Kaufman, M Muñoz, JI Lai, H Knoderer, C Sandoval, AR Chawla, B Nguyen, Y Zhou, E Ravenberg, LM Litchfield, L Smyth, SA Wander	03/20/2025
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	L Pusztai, JR Hoag, KS Albain, WE Barlow, SM Stemmer, A Meisner, GN Hortobagyi, S Shak, JM Rae, R Baehner, P Sharma, KM Kalinsky	03/10/2025
Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K-Mutated Tumor. JCO precision oncology	CK McCourt, J Gross, K Kalinsky, P Guan, LM McShane, V Wang, PJ O'Dwyer, MT Lahey, C Maican, X Bu, D Patton, LN Harris	03/01/2025
Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer. Scientific reports	V Jones, HH Yin, YC Yuan, Y Wang, SM Li, D Aljaber, A Sanchez, C Quinones, D Schmolze, Y Yuan, J Mortimer, L Yee, L Kruper, T Jovanovic-Talisman, J Tomsic, N Sanchez, T Chavez, RM O'Regan, QJ Khan, M Davis, K Kalinsky, J Meisel, R Kittles, L Rodriguez-Rodriguez, V Seewaldt	02/28/2025
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials. European journal of cancer (Oxford, England : 1990)	LL Hart, SA Im, SM Tolaney, M Campone, T Pluard, B Sousa, G Freyer, T Decker, K Kalinsky, G Sopher, M Gao, H Hu, S Kuemmel	02/25/2025
Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	A Thomas, EL Mayer, A DeMichele, N Harbeck, G Curigliano, M Ignatiadis, V Adam, Y Zhou, TP Brown, L Gilham, BH Chua, K Kalinsky, AC Wolff, S O'Reilly	02/10/2025
Use of a Smartphone Application to Promote Adherence to Oral Medications in Patients With Breast Cancer. JCO oncology practice	C Sathe, R Raghunathan, S Ulene, F McAuley, KA Bhatt, JE McGuinness, MS Trivedi, N Vasan, KM Kalinsky, KD Crew, KF Faheem, E Harden, C Law, DL Hershman, MK Accordino	02/01/2025
"Nailing down" risk and improving outcomes in early-stage breast cancer. Journal of the National Cancer Institute	SL Graff, S Tinianov, K Kalinsky	02/01/2025
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	A Bardia, K Jhaveri, SA Im, S Pernas, M De Laurentiis, S Wang, N Martínez Jañez, G Borges, DW Cescon, M Hattori, YS Lu, E Hamilton, Q Zhang, J Tsurutani, K Kalinsky, PE Rubini Liedke, L Xu, RM Fairhurst, S Khan, N Denduluri, HS Rugo, B Xu, B Pistilli	01/20/2025
Top advances of the year: Breast cancer. Cancer	CR Farley, E Sakach, N Ridge, R Sacks, K Kalinsky	01/01/2025
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nature medicine	K Khoury, JL Meisel, C Yau, HS Rugo, R Nanda, M Davidian, B Tsiatis, AJ Chien, AM Wallace, M Arora, M Rozenblit, DL Hershman, A Zimmer, AS Clark, H Beckwith, AD Elias, E Stringer-Reasor, JC Boughey, C Nangia, C Vaklavas, C Omene, KS Albain, KM Kalinsky, C Isaacs, J Tseng, ET Roussos Torres, B Thomas, A Thomas, A Sanford, R Balassanian, C Ewing, K Yeung, C Sauder, T Sanft, L Pusztai, MS Trivedi, A Outhaythip, W Li, N Onishi, AL Asare, P Beineke, P Norwood, L Brown-Swigart, GL Hirst, JB Matthews, B Moore, W Fraser Symmans, E Price, C Beedle, J Perlmutter, P Pohlmann, RA Shatsky, A DeMichele, D Yee, LJ van 't Veer, NM Hylton, LJ Esserman	12/01/2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nature medicine	RA Shatsky, MS Trivedi, C Yau, R Nanda, HS Rugo, M Davidian, B Tsiatis, AM Wallace, AJ Chien, E Stringer-Reasor, JC Boughey, C Omene, M Rozenblit, K Kalinsky, AD Elias, C Vaklavas, H Beckwith, N Williams, M Arora, C Nangia, ET Roussos Torres, B Thomas, KS Albain, AS Clark, C Falkson, DL Hershman, C Isaacs, A Thomas, J Tseng, A Sanford, K Yeung, S Boles, YY Chen, L Huppert, N Jahan, C Parker, K Giridhar, FM Howard, MM Blackwood, T Sanft, W Li, N Onishi, AL Asare, P Beineke, P Norwood, L Brown-Swigart, GL Hirst, JB Matthews, B Moore, WF Symmans, E Price, D Heditsian, B LeStage, J Perlmutter, P Pohlmann, A DeMichele, D Yee, LJ van 't Veer, NM Hylton, LJ Esserman	12/01/2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	KL Jhaveri, MK Accordino, PL Bedard, A Cervantes, V Gambardella, E Hamilton, A Italiano, K Kalinsky, IE Krop, M Oliveira, P Schmid, C Saura, NC Turner, A Varga, S Cheeti, S Hilz, KE Hutchinson, Y Jin, S Royer-Joo, U Peters, N Shankar, JL Schutzman, D Juric	11/20/2024
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast cancer research and treatment	K Kalinsky, L Spring, C Yam, MA Bhave, I Ntalla, C Lai, N Sjekloca, B Stwalley, M Stokes, A Taylor, R Nanda	11/01/2024
Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma. European journal of nuclear medicine and molecular imaging	A Mushtaq, IO Lawal, S Muzahir, SC Friend, M Bhave, JL Meisel, MA Torres, TM Styblo, CL Graham, K Kalinsky, J Switchenko, GA Ulaner, DM Schuster	11/01/2024
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. The New England journal of medicine	NC Turner, SA Im, C Saura, D Juric, S Loibl, K Kalinsky, P Schmid, S Loi, P Sunpaweravong, A Musolino, H Li, Q Zhang, Z Nowecki, R Leung, E Thanopoulou, N Shankar, G Lei, TJ Stout, KE Hutchinson, JL Schutzman, C Song, KL Jhaveri	10/31/2024
Tuning Immune-Cold Tumor by Suppressing USP10/B7-H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs. Advanced science (Weinheim, Baden-Wurttemberg, Germany)	L Zeng, Y Zhu, X Cui, J Chi, A Uddin, Z Zhou, X Song, M Dai, M Cristofanilli, K Kalinsky, Y Wan	10/01/2024
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast cancer research and treatment	MA Bhave, JCF Quintanilha, H Tukachinsky, G Li, T Scott, JS Ross, L Pasquina, RSP Huang, H McArthur, MA Levy, RP Graf, K Kalinsky	10/01/2024
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nature reviews. Clinical oncology	MR Lloyd, K Jhaveri, K Kalinsky, A Bardia, SA Wander	10/01/2024
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO molecular medicine	Y Tai, A Chow, S Han, C Coker, W Ma, Y Gu, V Estrada Navarro, M Kandpal, H Hibshoosh, K Kalinsky, K Manova-Todorova, A Safonov, EM Walsh, M Robson, L Norton, R Baer, T Merghoub, AK Biswas, S Acharyya	08/01/2024
The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO oncology practice	A Loeser, JS Kim, J Peppercorn, ME Burkard, A Niemierko, D Juric, K Kalinsky, H Rugo, L Glenn, C Hodgdon, J Maues, S Johnson, N Padron, K Parekh, M Lustberg, A Bardia	07/01/2024
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer	HS Rugo, SM Tolaney, D Loirat, K Punie, A Bardia, SA Hurvitz, J O'Shaughnessy, J Cortés, V Diéras, LA Carey, L Gianni, MJ Piccart, S Loibl, DM Goldenberg, Q Hong, M Olivo, LM Itri, K Kalinsky	06/06/2024
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	A Bardia, HS Rugo, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, K Kalinsky, J Cortés, JO Shaughnessy, V Diéras, LA Carey, L Gianni, M Piccart-Gebhart, S Loibl, OK Yoon, Y Pan, S Hofsess, SC Phan, SA Hurvitz	05/20/2024
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer	SA Hurvitz, A Bardia, K Punie, K Kalinsky, LA Carey, HS Rugo, V Diéras, S Phan, R Delaney, Y Zhu, SM Tolaney	04/25/2024
Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers. The Journal of clinical investigation	Y Zhu, A Banerjee, P Xie, AA Ivanov, A Uddin, Q Jiao, JJ Chi, L Zeng, JY Lee, Y Xue, X Lu, M Cristofanilli, WJ Gradishar, CJ Henry, TW Gillespie, MA Bhave, K Kalinsky, H Fu, I Bahar, B Zhang, Y Wan	03/26/2024
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Future oncology (London, England)	A Bardia, K Jhaveri, K Kalinsky, S Pernas, J Tsurutani, B Xu, E Hamilton, SA Im, Z Nowecki, J Sohn, M Laurentiis, NM Jañez, B Adamo, KS Lee, KH Jung, G Rubovszky, LM Tseng, YS Lu, Y Yuan, MJ Maxwell, V Haddad, SS Khan, HS Rugo, B Pistilli	03/01/2024
Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer. Breast cancer research and treatment	MK Accordino, S Lee, CS Leu, B Levin, MS Trivedi, KD Crew, K Kalinsky, R Raghunathan, K Faheem, E Harden, A Taboada, BD de Oliveira, E Larson, L Franks, E Honan, C Law, DL Hershman	02/01/2024
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications	GD Lewis, G Li, J Guo, SF Yu, CT Fields, G Lee, D Zhang, PS Dragovich, T Pillow, B Wei, J Sadowsky, D Leipold, T Wilson, A Kamath, M Mamounas, MV Lee, O Saad, V Choeurng, A Ungewickell, S Monemi, L Crocker, K Kalinsky, S Modi, KH Jung, E Hamilton, P LoRusso, I Krop, MM Schutten, R Commerford, MX Sliwkowski, E Cho	01/11/2024
Moving precision forward: extending next generation sequencing to operable disease in less common breast cancer subtypes. Annals of oncology : official journal of the European Society for Medical Oncology	A Thomas, R Shatsky, K Kalinsky	01/01/2024
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic advances in medical oncology	A Bardia, L Pusztai, K Albain, EM Ciruelos, SA Im, D Hershman, K Kalinsky, C Isaacs, D Loirat, L Testa, E Tokunaga, J Wu, H Dry, W Barlow, R Kozarski, M Maxwell, N Harbeck, P Sharma	01/01/2024
CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed? Current treatment options in oncology	E Sakach, M Keskinkilic, S Wood, M Canning, K Kalinsky	09/01/2023
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	K Kalinsky, MK Accordino, C Chiuzan, PS Mundi, E Sakach, C Sathe, H Ahn, MS Trivedi, Y Novik, A Tiersten, G Raptis, LN Baer, SY Oh, AB Zelnak, KB Wisinski, E Andreopoulou, WJ Gradishar, E Stringer-Reasor, SA Reid, A O'Dea, R O'Regan, KD Crew, DL Hershman	08/20/2023
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world. Breast cancer research and treatment	M Kruse, EN Smyth, L Bowman, S Gautam, CM Guimaraes, AR Nisbett, MD Fisher, ZL Cui, KM Sheffield, K Kalinsky	08/01/2023
Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA oncology	R Jagsi, WE Barlow, WA Woodward, E Connolly, R Mahtani, D Shumway, C Speers, SR Stecklein, Y Zeidan, H Zhang, P Sharma, L Pusztai, GN Hortobagyi, K Kalinsky	08/01/2023
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies. Cancer discovery	PS Mundi, FS Dela Cruz, A Grunn, D Diolaiti, A Mauguen, AR Rainey, K Guillan, A Siddiquee, D You, R Realubit, C Karan, MV Ortiz, EF Douglass, M Accordino, S Mistretta, F Brogan, JN Bruce, CI Caescu, RD Carvajal, KD Crew, G Decastro, M Heaney, BS Henick, DL Hershman, JY Hou, FM Iwamoto, JG Jurcic, RP Kiran, MD Kluger, T Kreisl, N Lamanna, AB Lassman, EA Lim, GA Manji, GM McKhann, JM McKiernan, AI Neugut, KP Olive, T Rosenblat, GK Schwartz, CA Shu, MB Sisti, A Tergas, RM Vattakalam, M Welch, S Wenske, JD Wright, P Canoll, H Hibshoosh, K Kalinsky, M Aburi, PA Sims, MJ Alvarez, AL Kung, A Califano	06/02/2023
Advances in SERDs and other novel endocrine therapies. Clinical advances in hematology & oncology : H&O	K Kalinsky	06/01/2023
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor. Nature cancer	J Silva, J Yu, K Kalinsky	06/01/2023
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. JCO precision oncology	JO Brett, TD Dubash, GN Johnson, A Niemierko, V Mariotti, LSL Kim, J Xi, A Pandey, S Dunne, A Nasrazadani, MR Lloyd, A Kambadakone, LM Spring, DS Micalizzi, ML Onozato, D Che, U Nayar, A Brufsky, K Kalinsky, CX Ma, J O'Shaughnessy, HS Han, AJ Iafrate, LY Ryan, D Juric, B Moy, LW Ellisen, S Maheswaran, N Wagle, DA Haber, A Bardia, SA Wander	05/01/2023
A Discordant Pattern of Uptake on 68 Ga-PSMA PET/CT Versus 18 F-Fluciclovine PET/CT in Radiation-Induced Hepatitis : Implications for Early Postradiotherapy Imaging-Based Response Assessment. Clinical nuclear medicine	OA Adediran, IO Lawal, S Muzahir, MA Bhave, S Friend, B Fielder, J Meisel, MA Torres, TM Styblo, C Graham, A Holbrook, K Kalinsky, RJ Crowe, GA Ulaner, DM Schuster	04/01/2023
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. ESMO open	JR Hecht, SS Raman, A Chan, K Kalinsky, JF Baurain, MM Jimenez, MM Garcia, MD Berger, UM Lauer, A Khattak, A Carrato, Y Zhang, K Liu, E Cha, A Keegan, S Bhatta, CP Strassburg, A Roohullah	04/01/2023
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future oncology (London, England)	N Turner, C Huang-Bartlett, K Kalinsky, M Cristofanilli, G Bianchini, S Chia, H Iwata, W Janni, CX Ma, EL Mayer, YH Park, S Fox, X Liu, S McClain, FC Bidard	03/01/2023
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer	TZ Zeleke, Q Pan, C Chiuzan, M Onishi, Y Li, H Tan, MJ Alvarez, E Honan, M Yang, PL Chia, P Mukhopadhyay, S Kelly, R Wu, K Fenn, MS Trivedi, M Accordino, KD Crew, DL Hershman, M Maurer, S Jones, A High, J Peng, A Califano, K Kalinsky, J Yu, J Silva	02/01/2023
Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity. Science advances	Z Fu, S Chen, Y Zhu, D Zhang, P Xie, Q Jiao, J Chi, S Xu, Y Xue, X Lu, X Song, M Cristofanilli, WJ Gradishar, K Kalinsky, Y Yin, B Zhang, Y Wan	01/06/2023
Racial Disparities in Clinical Outcomes on Investigator-Initiated Breast Cancer Clinical Trials at an Urban Medical Center. Clinical breast cancer	J Aldrich, P Ekpo, M Rupji, JM Switchenko, MA Torres, K Kalinsky, MA Bhave	01/01/2023
A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-Fluciclovine, 68Ga-PSMA, and 18F-FDG in the Uterus and Adnexa. Clinical nuclear medicine	IO Lawal, OA Adediran, S Muzahir, S Friend, MA Bhave, J Meisel, MA Torres, TM Styblo, C Graham, A Holbrook, K Kalinsky, B Fielder, RJ Crowe, GA Ulaner, DM Schuster	01/01/2023
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. European journal of cancer (Oxford, England : 1990)	S Loibl, D Loirat, SM Tolaney, K Punie, M Oliveira, HS Rugo, A Bardia, SA Hurvitz, AM Brufsky, K Kalinsky, J Cortés, JA O'Shaughnessy, V Dieras, LA Carey, L Gianni, M Gharaibeh, L Preger, S Phan, L Chang, L Shi, MJ Piccart	01/01/2023
The role of immune checkpoint inhibition in triple negative breast cancer. Expert review of anticancer therapy	K Tarekegn, M Keskinkilic, TJ Kristoff, ST Evans, K Kalinsky	01/01/2023
Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC). Breast cancer research and treatment	AL Loeser, L Gao, A Bardia, ME Burkard, KM Kalinsky, J Peppercorn, HS Rugo, M Carlson, J Cowden, L Glenn, J Maues, S McGlown, A Ni, N Padron, M Lustberg	12/01/2022
Trop-2 as a Therapeutic Target in Breast Cancer. Cancers	E Sakach, R Sacks, K Kalinsky	11/30/2022
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. NPJ breast cancer	T Qing, T Karn, M Rozenblit, J Foldi, M Marczyk, NL Shan, K Blenman, U Holtrich, K Kalinsky, F Meric-Bernstam, L Pusztai	11/07/2022
Study Protocol: Efficacy and Safety of Radioembolization (REM) as an Early Modality (EM) Therapy for Metastatic Breast Cancer (BR) to the Liver with Y90 (REMEMBR Y90). Cardiovascular and interventional radiology	R Wu, K Gogineni, J Meisel, S Szabo, M Thirunavu, S Friend, Z Bercu, I Sethi, N Natarajan, J Switchenko, J Levy, E Abdalla, L Weakland, K Kalinsky, N Kokabi	11/01/2022
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	NL Henry, MR Somerfield, Z Dayao, A Elias, K Kalinsky, LM McShane, B Moy, BH Park, KM Shanahan, P Sharma, R Shatsky, E Stringer-Reasor, M Telli, NC Turner, A DeMichele	09/20/2022
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast cancer research and treatment	J O'Shaughnessy, A Brufsky, HS Rugo, SM Tolaney, K Punie, S Sardesai, E Hamilton, D Loirat, T Traina, R Leon-Ferre, SA Hurvitz, K Kalinsky, A Bardia, S Henry, I Mayer, Y Zhu, S Phan, J Cortés	09/01/2022
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A. JCO oncology practice	R Raab, N Ismaila, F Andre, V Stearns, K Kalinsky	09/01/2022
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer	HS Rugo, SM Tolaney, D Loirat, K Punie, A Bardia, SA Hurvitz, J O'Shaughnessy, J Cortés, V Diéras, LA Carey, L Gianni, MJ Piccart, S Loibl, DM Goldenberg, Q Hong, M Olivo, LM Itri, K Kalinsky	08/29/2022
Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer. Clinical breast cancer	RS Vanguri, KM Fenn, MR Kearney, Q Wang, H Guo, DK Marks, C Chin, CF Alcus, JB Thompson, CS Leu, H Hibshoosh, KM Kalinsky, JC Mathews, S Nadeem, TJ Hollmann, EP Connolly	08/01/2022
Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology	DW Cescon, K Kalinsky, AM DeMichele	08/01/2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Annals of oncology : official journal of the European Society for Medical Oncology	D Trapani, MA Franzoi, HJ Burstein, LA Carey, S Delaloge, N Harbeck, DF Hayes, K Kalinsky, L Pusztai, MM Regan, I Sestak, T Spanic, J Sparano, S Jezdic, N Cherny, G Curigliano, F Andre	07/01/2022
Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer. Breast cancer research and treatment	JE McGuinness, V Ro, S Mutasa, S Pan, J Hu, MS Trivedi, MK Accordino, K Kalinsky, DL Hershman, RS Ha, KD Crew	07/01/2022
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. NPJ breast cancer	LA Carey, D Loirat, K Punie, A Bardia, V Diéras, F Dalenc, JR Diamond, C Fontaine, G Wang, HS Rugo, SA Hurvitz, K Kalinsky, J O'Shaughnessy, S Loibl, L Gianni, M Piccart, Y Zhu, R Delaney, S Phan, J Cortés	06/09/2022
Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082]. Annals of oncology : official journal of the European Society for Medical Oncology	MJ Piccart, K Kalinsky, R Gray, WE Barlow, C Poncet, F Cardoso, E Winer, J Sparano	06/01/2022
Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ Assay. Clinical breast cancer	M Wooster, JE McGuinness, KM Fenn, VM Singh, LE Franks, S Lee, D Cieremans, AB Lassman, DL Hershman, KD Crew, MK Accordino, MS Trivedi, F Iwamoto, MR Welch, A Haggiagi, RD Schultz, L Huynh, E Sales, D Fisher, JA Mayer, T Kreisl, K Kalinsky	06/01/2022
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	F Andre, N Ismaila, KH Allison, WE Barlow, DE Collyar, S Damodaran, NL Henry, K Jhaveri, K Kalinsky, NM Kuderer, A Litvak, EL Mayer, L Pusztai, R Raab, AC Wolff, V Stearns	06/01/2022
Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer. Breast cancer research and treatment	TTA Nguyen, LM Postlewait, C Zhang, JL Meisel, R O'Regan, S Badve, K Kalinsky, X Li	04/01/2022
Individualizing Adjuvant Therapy in Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Node-Positive Breast Cancer. JCO oncology practice	K Gogineni, K Kalinsky	04/01/2022
Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy? Therapeutic advances in medical oncology	C Taylor, J Meisel, K Kalinsky	01/01/2022
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. The New England journal of medicine	K Kalinsky, WE Barlow, JR Gralow, F Meric-Bernstam, KS Albain, DF Hayes, NU Lin, EA Perez, LJ Goldstein, SKL Chia, S Dhesy-Thind, P Rastogi, E Alba, S Delaloge, M Martin, CM Kelly, M Ruiz-Borrego, M Gil-Gil, CH Arce-Salinas, EGC Brain, ES Lee, JY Pierga, B Bermejo, M Ramos-Vazquez, KH Jung, JM Ferrero, AF Schott, S Shak, P Sharma, DL Lew, J Miao, D Tripathy, L Pusztai, GN Hortobagyi	12/16/2021
Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Clinical breast cancer	R Mahtani, M Kittaneh, K Kalinsky, E Mamounas, S Badve, C Vogel, E Lower, L Schwartzberg, M Pegram	10/01/2021
Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer. Breast cancer research and treatment	MR Kearney, JE McGuinness, K Kalinsky	08/01/2021
Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer. Breast cancer research and treatment	JE McGuinness, ML Altoe, A Marone, LE Franks, SM Lee, HK Kim, M Tejada, MS Trivedi, MK Accordino, KD Crew, DL Hershman, AH Hielscher, K Kalinsky	08/01/2021
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Breast cancer research and treatment	M Kearney, L Franks, S Lee, A Tiersten, DF Makower, T Cigler, P Mundi, DC Chi, A Goel, P Klein, E Andreopoulou, J Sparano, M Trivedi, M Accordino, A Califano, DL Hershman, J Silva, K Kalinsky	08/01/2021
Care Delivery Impact of the COVID-19 Pandemic on Breast Cancer Care. JCO oncology practice	T Satish, R Raghunathan, JG Prigoff, JD Wright, GA Hillyer, MS Trivedi, K Kalinsky, KD Crew, DL Hershman, MK Accordino	08/01/2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. Journal for immunotherapy of cancer	LA Emens, S Adams, A Cimino-Mathews, ML Disis, ME Gatti-Mays, AY Ho, K Kalinsky, HL McArthur, EA Mittendorf, R Nanda, DB Page, HS Rugo, KM Rubin, H Soliman, PA Spears, SM Tolaney, JK Litton	08/01/2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer cell	L Pusztai, C Yau, DM Wolf, HS Han, L Du, AM Wallace, E String-Reasor, JC Boughey, AJ Chien, AD Elias, H Beckwith, R Nanda, KS Albain, AS Clark, K Kemmer, K Kalinsky, C Isaacs, A Thomas, R Shatsky, TL Helsten, A Forero-Torres, MC Liu, L Brown-Swigart, EF Petricoin, JD Wulfkuhle, SM Asare, A Wilson, R Singhrao, L Sit, GL Hirst, S Berry, A Sanil, AL Asare, JB Matthews, J Perlmutter, M Melisko, HS Rugo, RB Schwab, WF Symmans, D Yee, LJ Van't Veer, NM Hylton, AM DeMichele, DA Berry, LJ Esserman	07/12/2021
Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer. Breast cancer research and treatment	MB Hopson, S Lee, M Accordino, M Trivedi, M Maurer, KD Crew, DL Hershman, K Kalinsky	07/01/2021
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan. Expert opinion on biological therapy	JE McGuinness, K Kalinsky	07/01/2021
Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer. Clinical breast cancer	S Bose, K Kalinsky	06/01/2021
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. Clinical cancer research : an official journal of the American Association for Cancer Research	SM Tolaney, K Kalinsky, VG Kaklamani, DR D'Adamo, G Aktan, ML Tsai, RM O'Regan, PA Kaufman, ST Wilks, E Andreopoulou, DA Patt, Y Yuan, G Wang, C Savulsky, D Xing, E Kleynerman, V Karantza, S Diab	06/01/2021
Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy. Nature cancer	JI Griffiths, J Chen, PA Cosgrove, A O'Dea, P Sharma, C Ma, M Trivedi, K Kalinsky, KB Wisinski, R O'Regan, I Makhoul, LM Spring, A Bardia, FR Adler, AL Cohen, JT Chang, QJ Khan, AH Bild	06/01/2021
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. The New England journal of medicine	A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, SD Sardesai, K Kalinsky, AB Zelnak, R Weaver, T Traina, F Dalenc, P Aftimos, F Lynce, S Diab, J Cortés, J O'Shaughnessy, V Diéras, C Ferrario, P Schmid, LA Carey, L Gianni, MJ Piccart, S Loibl, DM Goldenberg, Q Hong, MS Olivo, LM Itri, HS Rugo	04/22/2021
Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes. Clinical cancer research : an official journal of the American Association for Cancer Research	ML Altoe, K Kalinsky, A Marone, HK Kim, H Guo, H Hibshoosh, M Tejada, KD Crew, MK Accordino, MS Trivedi, DL Hershman, AH Hielscher	04/01/2021
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. Journal of the National Comprehensive Cancer Network : JNCCN	SA Wander, HS Han, ML Zangardi, A Niemierko, V Mariotti, LSL Kim, J Xi, A Pandey, S Dunne, A Nasrazadani, A Kambadakone, C Stein, MR Lloyd, M Yuen, LM Spring, D Juric, I Kuter, I Sanidas, B Moy, T Mulvey, N Vidula, NJ Dyson, LW Ellisen, S Isakoff, N Wagle, A Brufsky, K Kalinsky, CX Ma, J O'Shaughnessy, A Bardia	03/24/2021
When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	S Obeng-Gyasi, CE Coles, J Jones, R Sacks, S Lightowlers, JM Bliss, AM Brunt, JS Haviland, AM Kirby, K Kalinsky	03/01/2021
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. JAMA oncology	K Kalinsky, F Hong, CK McCourt, JC Sachdev, EP Mitchell, JA Zwiebel, LA Doyle, LM McShane, S Li, RJ Gray, LV Rubinstein, D Patton, PM Williams, SR Hamilton, BA Conley, PJ O'Dwyer, LN Harris, CL Arteaga, AP Chen, KT Flaherty	02/01/2021
Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography. Breast cancer research : BCR	ML Altoe, K Kalinsky, A Marone, HK Kim, H Guo, H Hibshoosh, M Tejada, KD Crew, MK Accordino, MS Trivedi, DL Hershman, AH Hielscher	01/31/2021
On the Road to Precision: Understanding the Biology Driving Genomic Assays. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	K Kalinsky, A Thomas, DW Cescon	01/10/2021
Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin. Cancer investigation	DK Marks, J Kucharczyk, P Kim, DI Chyong, RD Gartrell, Y Lu, H Hibshoosh, H Guo, TRJ Evans, J Lopez, R Kristeleit, E Connolly, Y Saenger, K Kalinsky	01/01/2021
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. Frontiers in oncology	SM Tolaney, M Beeram, JT Beck, A Conlin, EC Dees, SL Puhalla, BN Rexer, HA Burris, K Jhaveri, T Helsten, C Becerra, K Kalinsky, KN Moore, AM Manuel, A Lithio, GL Price, SC Chapman, LM Litchfield, MP Goetz	01/01/2021
Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. Frontiers in oncology	DW Cescon, K Kalinsky, HA Parsons, KL Smith, PA Spears, A Thomas, F Zhao, A DeMichele	01/01/2021

Awards

Dr. Kalinsky is a fellow of the American Society of Clinical Oncology. He is a recipient of the Ewig Clinical Scholar Teaching Award from Columbia University, NCI Cancer Clinical Investigator Team Leadership Award, Physician of Impact Award from Susan G. Komen Greater NYC, and SWOG Career Engagement Award.

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	05/05/2025	Very engaging
One star One star One star One star One star	04/18/2025	Truly exceptional care. Very dedicated to patient wellbeing and consistently goes above and beyond. Incredibly knowledgeable with extensive research experience, yet remains humble and approachable. A rare combination of expertise and compassion-couldn't ask for more. Highly recommend.
One star One star One star One star One star	03/24/2025	I recommend everyone to Dr. Kalinsky and Winship
One star One star One star One star One star	03/12/2025	Dr. Kevin Kalinsky is knowledgeable, caring, and has exceptional bedside manner! I thank God for Dr. Kalinsky!
One star One star One star One star One star	01/31/2025	Dr. Kalinsky has a superb bedside manner. He took an in depth history and thoroughly shared treatment options for now and shared next steps should the current regimen stop working. I left with a clearer understanding of my disease and affirmation of my treatment plan. I deeply appreciated his active listening skills and compassionate approach. It was a very patient-centered experience.
One star One star One star One star One star	01/27/2025	Dr. Kalinsky is a top notch clinician, very committed to patient care, very professional yet approachable, and humble. He truly goes above and beyond to fix problems across different departments like ICC, admins in Research and even approaches leadership as need be. Cannot ask for more!
One star One star One star One star One star	01/26/2025	Dr. Kalinsky spent a lot of time with us, answering our many questions quite patiently and completely.Pharmacist very carefully went over medications I will be on, including potential side effects.Met other staff members. Quite impressed with the team--more like a family.
One star One star One star One star One star	01/24/2025	I would be lost without Dr. Kalinsky.
One star One star One star One star One star	01/12/2025	Felt he listened attentively, physically observed and assessed next steps needed.
One star One star One star One star One star	01/11/2025	Dr. Kalinsky is very compassionate. He made sure I understood the pros and cons of changing medication and the side effects.
One star One star One star One star One star	01/08/2025	Dr was outstanding building was very secure and outstanding
One star One star One star One star One star	01/01/2025	Dr. Kalinsky is the very best!
One star One star One star One star One star	01/01/2025	Physician was thorough with explanation of treatment; included me in matters of the discussion showed concern for clarity; made necessary referrals follow of a previous referral for what can be Included In treatment. Had team members come In to discuss medication information; had social worker come in to discuss home health care meal delivery and follow-up with an agency with whom I am registered with for other pertinent matters.
One star One star One star One star One star	12/27/2024	Dr. Kalinsky is a great doctor, very detailed and caring. He showed he looked at my case before meeting me and put some thoughts on it even during Christmas. He explained clearly his thoughts and plan, used data to show us the effectiveness of certain therapy, and answered all our questions without rushing us. He is an excellent doctor! So glad that I chose him!
One star One star One star One star One star	12/04/2024	My experience with Dr.Kalinsky and his staff is always pleasant, informative and productive.
One star One star One star One star One star	11/29/2024	Dr. Kalinsky is outstanding, and I feel very fortunate to have him as my doctor.
One star One star One star One star One star	11/10/2024	Provider went out of his way to get me scheduled quickly and thoroughly answered my questions.
One star One star One star One star One star	11/05/2024	It was apparent that the doctor had studied my medical history prior to my appointment. This was very reassuring to me.
One star One star One star One star Empty star	11/02/2024	I have NEVER had a bad experience at EMORY HHOSPITAL in the 2 years I have been going there for cancer treatments
One star One star One star One star One star	10/25/2024	GOOD
One star One star One star One star One star	10/23/2024	Dr. Kalinski has always listened, explained things and been kind and gentle, Another plus is he has great humor! I have always felt confident with him as my doctor, which is very important! A++
One star One star One star One star One star	10/23/2024	Very friendly
One star One star One star One star One star	10/23/2024	Dr. Kalinsky is always very caring and takes time to answer my questions and concerns.
One star One star One star One star One star	09/27/2024	Both Drs. Kalinsky and Styblo are very patient oriented, soliciting questions and providing easily understood advice and instructions. I feel incorporated into a team in which I am welcomed and respected. I have yet to ask a question that wasn't answered. I am very happy that I chose Emory for care.
One star One star One star One star One star	09/27/2024	Dr Kalinsky is very professional and thorough. He has empathy and compassion for his patients and is willing to go the extra mile to make sure I understand all the recommendations.
One star One star One star One star One star	09/08/2024	Dr. Kalinski always shows concern & listens attentively.
One star One star One star One star One star	09/04/2024	Dr. Kalinsky is awesome!
One star One star One star One star One star	08/28/2024	Dr. Kalinsky is the freaking best.
One star One star One star One star One star	08/09/2024	I, literally, trust Dr. Kalinsky with my life. He is patient, kind, and most importantly, is one of the very best doctors I've encountered anywhere.
One star One star One star One star One star	07/26/2024	Exceptional!
One star One star One star One star One star	07/24/2024	Awesome service
One star One star One star One star One star	07/11/2024	Excellent experience in all areas.
One star One star One star One star One star	07/02/2024	Excellent Service!!
One star One star One star One star One star	06/28/2024	Dr kalinsky is the best!!!!
One star One star One star One star One star	06/28/2024	Exceptional care.
One star One star One star One star One star	06/26/2024	Dr. Kalinsky is a very caring, emphatic, knowledgeable, professional physician. I feel very fortunate that he is my physician.
One star One star One star One star One star	06/14/2024	As an expert in trauma-informed medical care, I value greatly Dr. Kalinsky's patient-centered care which very much focused on proving informed consent and autonomy.
One star One star One star One star One star	05/30/2024	Dr Kalinsky is outstanding. I am so fortunate to have him as my doctor. He listens, answers fully, never seems rushed. He's excellent in every respect.
One star One star One star One star One star	05/24/2024	All good
One star One star One star One star One star	05/24/2024	Excellent experience from parking until the end of my appointment. Every person I came in contact with was friendly, engaging, helpful, kind and smiled!
One star One star One star One star One star	05/17/2024	I would highly recommend Dr. Kalinsky to others.
One star One star One star One star One star	04/22/2024	Dr Kalinsky was very thorough and thoughtful. He went above and beyond with my concerns.
One star One star One star One star One star	04/17/2024	Emory very professional
One star One star One star One star One star	04/05/2024	The Physician Assistant asked about our problem, what action we have taken from our last visit to include all new and old medicine. The doctor took his time going over all options and what he would do and told us he would talk with our doctor.
One star One star One star One star One star	03/29/2024	I would recommend Dr. Kalinsky to anyone.
One star One star One star One star One star	03/15/2024	Good
One star One star One star One star One star	01/19/2024	Meeting Dr. Kalinsky was wonderful! What a caring, excellent Doctor he is! Everything about him is top notch! What a privilege it was to meet him!
One star One star One star One star One star	01/05/2024	Dr Kalinsky was awesome he was very patient and explained everything in detail.
One star One star One star One star One star	12/13/2023	Dr. Kalinsky was Awesome.
One star One star One star One star One star	12/01/2023	Dr. Kalinsky is perfect at what he does. He has expertise in his field but also a wonderful "bedside" manner of being thorough & explaining things without being condescending. I very much appreciate his approach to patient care.
One star One star One star One star One star	11/19/2023	Dr. Kalinsky is by far the best doctor I have ever seen. He is compassionate, smart and makes his patients feel like they are the most important. I am so thankful that Dr. Kalinsky is my doctor and Emory is lucky to have him on staff.
One star One star One star One star One star	11/19/2023	Dr. Kalinsky is outstanding, absolutely the most concerned, thoughtful and empathic physician.
One star One star One star One star One star	11/18/2023	Dr. Kalinsky answered every question and explained the treatment plan so that I could understand why I needed this particular treatment. He is very kind and compassionate
One star One star One star One star One star	11/11/2023	I would strongly encourage
One star One star One star One star One star	11/06/2023	Explain everything to begin almost to the end. MY DAUGHTER WAS VERY PLEASED WITH HIM
One star One star One star One star Empty star	11/05/2023	Dr Kalinsky was very caring and listened to my concerns.
One star One star One star One star One star	11/03/2023	Dr Kalinsky is very competent and is charming
One star One star One star One star One star	10/03/2023	Dr. Kalinsky was excellent!!!
One star One star One star One star One star	09/27/2023	Doctor Kalinsky was friendly and knowledgeable about my condition and treatment. He listened to my concerns and I left with a better understanding about my options.
One star One star One star One star One star	09/16/2023	Dr. Kalinsky is attentive, communicates very well and explains things so that they are easy to understand. He was very responsive every time I reached out with questions or health issues. I couldn't have asked for a better oncologist!
One star One star One star One star One star	09/01/2023	It was quite apparent that Dr. Kalinsky had read my entire file as he recounted all 13 years of my cancer journey prior to this visit. He discussed treatment options and even recommended a clinical trial at some point in the future. It was pretty amazing!
One star One star One star One star One star	08/26/2023	Kalinsky is the best. So thankful for him.
One star One star One star One star One star	08/25/2023	Dr. Kalinsky is always compassionate about my holistic health and inquires of ongoing anemia issue.
One star One star One star One star One star	08/17/2023	Dr. Kalinsky listens with the care of being a human being talking with another human being. There is no "holier than thou" communication even though he is a highly educated and in-charge doctor.
One star One star One star One star One star	08/04/2023	Dr Kalinsky is wonderful!
One star One star One star One star One star	07/28/2023	Dr Kalinsky is not my primary oncologist, but he still took time to answer questions about my treatment plan
One star One star One star One star One star	07/04/2023	I highly recommend Dr. Kalinsky. All doctors, oncology and other specialties, need the empathy that he shows. Empathy training should be an annual required training.
One star One star One star One star One star	07/03/2023	Dr. Kalinsky listens to my concerns and goes above and beyond to make sure I am getting the best care possible.
One star One star One star One star One star	07/01/2023	Dr Kalinsky is both Knowledgeable & Professional